Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | VenBd shows significant improvement in PFS for R/R MM

Shaji Kumar • 7 Dec 2019
ASH 2019
Multiple Myeloma Bortezomib Dexamethasone Venetoclax
BELLINI

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the BELLINI trial (NCT02755597). The study evaluated the combination of venetoclax with bortezomib and dexamethasone (VenBd) in patients with relapsed/refractory multiple myeloma who received 1-3 prior therapies. Updated results continue to show significant improvement in progression-free survival, although the difference in overall survival is no longer significant. Dr Kumar reveals that a biomarker-based approach might be necessary for the selection of patients most likely to respond to venetoclax-based treatments. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Shaji Kumar

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:18
Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals